Efinopegdutide EFINO

An experimental injectable drug in human trials for obesity and fatty liver disease. Trial data show it significantly reduces liver fat and body weight, making it a candidate aimed specifically at liver health.

Also known as MK-6024

Effects Lose fat

Routes Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; development status uncertain

Reported range Phase II trials: up to 10 mg once weekly

Route Subcutaneous injection

Frequency Once weekly

Duration Trial durations of several months

Investigational GLP-1/glucagon dual agonist (Merck); not an approved product.

Where this comes from Published Phase II clinical trial data (Merck)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.